Thursday, February 11, 2021 Daily Archives

Improving and Intensifying Vaccine Purification By Implementing Affinity Chromatography

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Zoltan Gulyas, Field Applications Specialist, Thermo Fisher Scientific Vaccines are well-established tools in the fight to eradicate infectious diseases. Over the past few decades, vaccine production has advanced significantly, largely by the introduction of new molecule modalities. However, these new types of vaccine candidates often require multiple chromatographic steps to obtain the desired level of purity. Developing an efficient purification process using the classical surface chemistries such as ion exchange and hydrophobic interaction requires significant amounts of…

BMS gearing up to make Breyanzi at Bothell cell therapy plant

Bristol Myers-Squibb (BMS) has set a 24-day production target for Breyanzi and set up a digital platform to let physicians and patients track manufacture of the lymphoma cell therapy in real-time. The US Food and Drug Administration (FDA) cleared Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma this month. A BMS spokeswoman told us “BMS plans to manufacture Breyanzi for each individual patient at its state-of-the-art cellular immunotherapy manufacturing facilities, initially…

Rentschler catapults into the cell and gene therapy space through UK investment

German CDMO Rentschler will set up manufacturing capabilities at the UK’s Cell and Gene Therapy (CGT) Catapult, launching itself into the regenerative medicine space. Family-owned contract development and manufacturing organization (CDMO) Rentschler offers mammalian manufacturing and fill and finish services for biologics but has now expanded into cell and gene therapy production through a deal with the CGT Catapult, based in Stevenage, UK. Rentschler will establish its manufacturing capabilities – including adeno-associated virus (AAV) vector production – through “a significant…

Podcast: Industry veteran moves to Lykan Bioscience, and this time its personal!

In the latest episode of the BioProcess Insider Expression Platform, we explore the evolution of cell and gene therapy production with new COO of Lykan Bioscience, Patrick Lucy. From Repligen, to Lonza, to Pfenex, Patrick Lucy has had an illustrious career. His latest career move is to Lykan Bioscience, a Massachusetts-based contract Manufacturing Services Organization (MSO) and provider of end-to-end solution for cell-based therapies, where he took on the role of chief operating officer (COO) in January. In this podcast,…